Patients enrolled in a preventive drug list (PDL) benefit saw an 8.4% reduction in acute, preventable diabetes complication days, and PDL members residing in lower-income areas saw a 10.2% decrease compared with control members.
Lowering out-of-pocket (OOP) expenses for cardiometabolic medications could potentially lead to slight enhancements in near-term health results for commercially insured individuals with diabetes, according to a new study published in JAMA Health Forum.
Type 2 diabetes has seen a rise in prevalence over the past 2 decades, with pharmacotherapy playing a crucial role in managing complications. As acute and chronic diabetes complications increase, particularly among younger and socioeconomically disadvantaged populations, OOP costs remain a barrier to accessing essential medications. Employers have responded by adopting preventive drug lists (PDLs), which offer reduced OOP expenses for preventive medications, including those for diabetes. While prior research suggests increased medication fills with PDL adoption, its impact on health outcomes remains underexplored, especially for individuals with lower incomes.
The cohort study investigated the impact of a PDL value-based medication benefit on diabetes health outcomes. Specifically, there was an 8.4% reduction in acute, preventable diabetes complication days observed in the entire PDL group, as well as a 10.2% decrease among PDL members residing in lower-income areas. These findings are in comparison to matched control group members whose cardiometabolic medications continued to be subject to deductibles or copayments during the follow-up period.
The study was conducted using data from a large, national commercial health plan spanning from January 2004 to June 2017, focusing on patients aged 12 to 64 years with diabetes. Participants enrolled through employers adopting PDLs experienced reduced OOP costs for common cardiometabolic drugs, leading to increased usage and coverage of antidiabetic agents.
Among the 10,588 patients in the intervention group and 690,075 patients in the control group after matching and weighting, significant improvements were observed. From baseline to follow-up, the proportion of days covered by noninsulin antidiabetic agents increased by 4.7% (95% CI, 3.2%-6.2%) in the PDL group and by 7.3% (95% CI, 5.1%-9.5%) among PDL members from lower-income areas compared with controls. Higher usage of noninsulin antidiabetic agents also saw a substantial increase, rising by 11.3% (95% CI, 8.2%-14.5%) in the PDL group and by 15.2% (95% CI, 10.6%-19.8%) among members from lower-income areas compared with controls.
The PDL group also experienced an 8.4% relative reduction in complication days (95% CI, −13.9% to −2.8%) with an absolute reduction of −20.2 (95% CI, −34.3 to −6.2) per 1000 members per year compared with controls from baseline to follow-up. PDL members residing in lower-income areas had a similar relative reduction of 10.2% (95% CI, −17.4% to −3.0%) with an absolute reduction of −26.1 (95% CI, −45.8 to −6.5) per 1000 members per year.
According to the authors, these findings suggest that targeted cost-sharing reductions could play a crucial role in improving health outcomes for commercially insured patients with diabetes, especially those with lower incomes.
“Although we found that residents of lower-income areas with PDLs had a larger magnitude of reduction than counterparts residing in higher-income areas, effect estimates did not differ statistically,” the authors said. “Nevertheless, our results suggest that targeting out-of-pocket cost reductions to specific populations, in this case patients with diabetes from lower-income areas, might enhance health outcomes. Preventive drug lists might also benefit patients with other chronic illnesses at risk for treatment adherence–related complications, but further research is needed.”
Among the limitations of this study, the findings are applicable only to patients with diabetes enrolled in commercial health plans, limiting generalizability. Additionally, the assignment to PDL coverage was not random but rather determined by specific employers, potentially introducing selection bias. Although efforts were made to minimize this bias through matching and weighting, there may still be residual confounding. Further, the study relied on claims-based algorithms to identify PDL exposure, which may have introduced errors in group assignment. While the analyses suggest reliable identification of PDL adoption, the study's reliance on 1-year continuous enrollment could affect generalizability and bias results toward the null, and its focus on short-term outcomes necessitates longer-term studies with larger samples to comprehensively assess the impact of PDL enrollment on clinical outcomes.
Reference
Wharam JF, Argetsinger S, Lakoma M, Zhang F, Ross-Degnan D. Acute diabetes complications after transition to a value-based medication benefit. JAMA Health Forum. 2024;5(2):e235309. doi:10.1001/jamahealthforum.2023.5309
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Panel Addresses Minority Physician Shortage, Maternal Health at Senate Committee Hearing
May 15th 2024The senate hearing held by the US Senate Committee on Health, Education, Labor, and Pensions, led by Sen. Bernie Sanders (I, Vermont), chairman of the committee, and ranking member Sen. Bill Cassidy, MD, (R, Louisiana), addressed the critical issue of physician and health care worker shortages, as well as the maternal health crisis, in the US.
Read More